Curis (CRIS)

• Market cap: $26.1M
• 1 day: 0.33%
• 5 days: -14.44%
• 1 month: -16.76%
• 3 months: -47.88%
• 6 months: -61.31%
• Year to date: -75.26%
• 1 year: -74.61%
• 5 years: -90.00%
• 10 years: -97.65%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Employees: 49

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

5.52% less ownership

Funds ownership: 39.15% [Q2] → 33.62% (-5.52%) [Q3]

9% less funds holding

Funds holding: 34 [Q2] → 31 (-3) [Q3]

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

32% less capital invested

Capital invested by funds: $15.9M [Q2] → $10.8M (-$5.07M) [Q3]

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20 549% upside
• Avg. target: $20 549% upside
• High target: $20 549% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Edward White 26% 1-year accuracy 37 / 142 met price target

549% upside $20

Buy Reiterated

10 Dec 2024